سعر ستراكوبينا 2.5 مجم 30 قرص 2024

Strakopina apixaban 2.5 mg film-coated tablets, pack of 30 (Global Napi Pharmaceuticals / Global Advanced Pharmaceutical, Egypt): an oral direct factor Xa inhibitor anticoagulant.

• Reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Prophylaxis of DVT after hip or knee replacement surgery; treatment of DVT and PE and reduction in the risk of recurrence.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (>1%) in adults are related to bleeding.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Active pathological bleeding; severe hypersensitivity to apixaban (e.g. anaphylactic reactions).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: premature discontinuation increases the risk of thrombotic events; epidural or spinal haematoma may occur with neuraxial anaesthesia or spinal puncture.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Can cause serious, potentially fatal bleeding; not recommended with prosthetic heart valves or in triple-positive antiphospholipid syndrome.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Combined P-gp and strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir)Reduce 5 mg or 10 mg twice-daily doses by 50%; avoid in patients already on 2.5 mg twice daily.DailyMed (U.S. National Library of Medicine)
• Combined P-gp and strong CYP3A4 inducers (e.g. rifampin, carbamazepine, phenytoin, St John's wort)Avoid: decreased apixaban exposure increases the risk of stroke and thromboembolism.DailyMed (U.S. National Library of Medicine)
• Antiplatelet agents, fibrinolytics, heparin, aspirin and chronic NSAIDsIncrease the risk of bleeding.DailyMed (U.S. National Library of Medicine)

• Limited data are insufficient to inform drug-associated risks of major birth defects, miscarriage or adverse developmental outcomes; treatment may increase the risk of bleeding during pregnancy and delivery.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• No human data on presence in milk; apixaban accumulates in rat milk; breastfeeding is not recommended during treatment.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Apixaban: Selective, reversible inhibitor of free and clot-bound factor Xa and of prothrombinase activity, decreasing thrombin generation; no direct effect on platelet aggregation.